MDGL

Business Context and Reporting Period

Company: Madrigal Pharmaceuticals, Inc. (MDGL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Madrigal is a biopharmaceutical company focused on treating metabolic dysfunction-associated steatohepatitis (MASH). Its only approved product, Rezdiffra (resmetirom), received FDA accelerated approval in March 2024 and European Commission conditional marketing authorization in August 2025, with a commercial launch in Germany in September 2025. The company is advancing a pipeline of MASH candidates through business development and internal research.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net product revenue increased 71% quarter-over-quarter (QoQ) and 93% year-over-year (YoY) for the six-month period, driven by increased demand for Rezdiffra in the U.S. and the European launch.
• Expense Increases:
  • Cost of Sales: Increased 341% QoQ and 392% YoY (six months), primarily due to higher royalties payable to Roche and a $10.4 million inventory write-down for work-in-process not meeting quality specifications.
  • R&D Expenses: Increased 69% QoQ and 103% YoY (six months). The six-month increase included $79.3 million in one-time upfront business development payments for new licenses (CSPC, Pfizer, Ribocure, Arrowhead).
  • SG&A Expenses: Increased 47% QoQ and 53% YoY (six months), driven by investments in commercial activities (including direct-to-consumer marketing) and headcount expansion for the endocrinology field force.
• Debt Restructuring: In July 2025, the company repaid its Hercules Loan Facility ($121.7 million) and entered a new Financing Agreement with a $350 million initial term loan, resulting in higher interest expense ($7.9 million for Q2 2026 vs. $3.3 million in Q2 2025).
• EPS Revision: The company revised its net loss per share calculation to include Pre-Funded Warrants and Series A/B Preferred Stock in the weighted average shares outstanding, reducing the reported loss per share for prior periods.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur losses until revenue from Rezdiffra and future products is sufficient. Cash resources ($838.9 million) are deemed sufficient to fund operations for at least one year. The company plans to expand commercialization in Europe and pursue full FDA approval via outcomes data from the MAESTRO-NASH trial (expected 2028) and the MAESTRO-NASH OUTCOMES trial (expected 2027).
• Pipeline Expansion: Significant capital was deployed to acquire rights to MGL-2086 (GLP-1 agonist), ervogastat (DGAT-2 inhibitor), MGL-0795 (siRNA), and six additional siRNA programs. Upfront payments totaled approximately $255 million in the six months ended June 30, 2026.
• Risks & Contingencies:
  • Liquidity Covenants: The Financing Agreement requires maintaining a minimum unrestricted cash balance of $100 million.
  • Regulatory Approval: Full FDA approval depends on positive outcomes from ongoing trials; failure could impact commercialization.
  • Reimbursement: Market acceptance depends on reimbursement from third-party payors and pricing pressures.
  • Inventory Quality: A $10.4 million write-down highlights risks in manufacturing quality control.

Investor Verification Checklist

• Revenue Sustainability: Verify the trajectory of Rezdiffra sales growth against the backdrop of increasing royalty obligations to Roche.
• Inventory Valuation: Assess the impact of the $10.4 million inventory write-down on future cost of sales and manufacturing efficiency.
• Debt Covenants: Monitor compliance with the $100 million minimum unrestricted cash balance covenant under the new Financing Agreement.
• Pipeline Milestones: Track the progress of newly licensed assets (MGL-2086, ervogastat, MGL-0795) and the timing of expected outcomes data from MAESTRO-NASH trials.
• EPS Calculation: Confirm understanding of the revised EPS methodology including Pre-Funded Warrants and Preferred Stock.